Full TechWatch Presentation Guide (1 hour)

Please review the information below before creating a presentation for your <u>Full TechWatch</u> meeting. The information will guide you, so you can have a productive and interactive meeting with BARDA's staff. During your meeting, BARDA staff will engage in technical discussion during your presentation to provide guidance, seek clarification, or ask questions.

Timeline:

- **One week prior to your meeting:** send your draft presentation to the TechWatch team to review.
  - Please refer to your Meeting Invitation email for TechWatch Team contact info.
- **At least 24-48 hours prior to your meeting:**
  - **S**end your final presentation as a PowerPoint or PDF file to the TechWatch Team to allow USG colleagues time to review your slides in advance, AND
  - Upload your final presentation materials to the [BDR Stakeholder Portal](#).
- **On the day of the meeting:** please arrive 5 minute early to the meeting for the initial meeting frame-in, and to ensure an on time start.

General Guidance for Full TechWatch:

- The meeting will be 60 minutes in duration; 45 minutes max for presentation (includes technical discussion throughout) and 15 minutes for Q&A and closeout discussion.
- The presentation should be data-driven and should not exceed 30-40 slides
- Explain how your technology aligns with the requirements stated in a specific area of interest (AOI) in BARDA's [BAA](#) or [EZ-BAA](#).
- Review information on [Technology Readiness Level](#) to determine the stage of maturity of your development program.

Specific Slide Guidance for Full TechWatch:

Slide Content	# of Slides
Company Overview	1
Key Personnel	1
Product Pipeline Overview	1
Alignment *Specific AOI and/or BARDA's BAA or EZ-BAA, and TRL*	1
Animation *If possible, of how your technology works (i.e. MOA)*	1
Proof-of-Concept Data	8-12
Product Differentiation *Comparison with other competing technologies to define value proposition/ ROI to BARDA/USG (i.e., table where rows are attributes, columns are your technology vs. others; 3-4 max)*	1
Regulatory *FDA feedback on development plan, and regulatory strategy for approval/licensure/clearance*	1-2
Clinical Data/Development Plan	6-8
Manufacturing	1-2
Intellectual Property	1
Proposed Business Plan *For commercial sustainability if applicable*	1
Funding Landscape *High level review of estimated funding required to complete the development program/establish the capability through FDA licensure/approval/clearance*	1
Key Questions for BARDA *3-4 key questions*	1
Contact Details *Name, phone number, email address, website*	1